Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats

Canadian Journal of Physiology and Pharmacology

Volumn 94, Issue 8, 2015, Pages 907-917

  Shahataa, Mary Girgis ^a   Mostafa Hedeab, Gomaa ^a,b   Ali, Esam Fouaad ^c   Mahdi, Emad Ahmed ^d   Mahmoud, Fatma Abd Elhaleem ^c  

^a BENI SUEF UNIVERSITY   (Egypt)

^b JOUF UNIVERSITY   (Saudi Arabia)

^c CAIRO UNIVERSITY   (Egypt)

^d Beni Suef University   (Egypt)

Author keywords

Blood pressure; Body mass; Dyslipidaemia; Insulin resistance; Metabolic syndrome; Pioglitazone; Telmisartan; Uric acid

Indexed keywords

CHOLESTEROL; CREATININE; FRUCTOSE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PIOGLITAZONE; TELMISARTAN; TRIACYLGLYCEROL; URIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; GLUCOSE BLOOD LEVEL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; DRUG THERAPY, COMBINATION; FRUCTOSE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84979994195     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2016-0090     Document Type: Article

References (78)

1. Alam, S., Kabir, J., Mustafa, G., Gupta, U., Hasan, S., and Alam, A. 2016. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: a 1-year randomized control trial. Saudi J. Gastroenterol. 22(1): 69–76. doi:10.4103/1319-3767.173762. PMID:26831610.
2. Al-Hejjaj, W.K., Numan, I.T., Al-Sa’ad, R.Z., and Hussain, S.A. 2011. Antiinflammatory activity of telmisartan in rat models of experimentallyinduced chronic inflammation: comparative study with dexamethasone. Saudi Pharmaceut. J. 19(1): 29–34. doi:10.1016/j.jsps.2010.10.004.
3. Bähr, I.N., Tretter, P., Kruger, J., Stark, R.G., Schimkus, J., Unger, T., Kappert, K., Scholze, J., Parhofer, K.G., and Kintscher, U. 2011. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome. Hypertension, 58(4): 725–732. doi:10.1161/HYPERTENSIONAHA.111.173542. PMID:21876071.
4. Bailey, C.J. 2001. New pharmacologic agents for diabetes. Curr. Diab. Rep. 1(2): 119–126. doi:10.1007/s11892-001-0023-9.
5. Balasubramanian, T. 2003. Uric acid or 1-methyl uric acid in the urinary bladder increases serum glucose, insulin, true triglyceride, and total cholesterol levels in Wistar rats. Sci. World J. 3: 930–936. doi:10.1100/tsw.2003.90.
6. Barutçuoğlu, B., Parildar, Z., Mutaf, M.I., Özmen, D., Alıіoğ lu, E., Habif, S., and Bayindir, O. 2010. Effect of telmisartan on vascular endothelium in hypertensive and type 2 diabetic hypertensive patients. Turk. J. Med. Sci. 40(2): 239–248. doi:10.3906/sag-0807-11.
7. Benson, S.C., Pershadsingh, H.A., Ho, C.I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M.A., and Kurtz, T.W. 2004. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension, 43(5): 993–1002. doi: 10.1161/01.HYP.0000123072.34629.57. PMID:15007034.
8. Blessing, E., Preusch, M., Kranzhöfer, R., Kinscherf, R., Marx, N., Rosenfeld, M.E., Isermann, B., Weber, C.M., Kreuzer, J., Gräfe, J, et al. 2008. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis, 199(2): 295–303. doi:10.1016/j.atherosclerosis.2007.10.037. PMID:18093593.
9. Burgess, E.D., and Buckley, S. 2000. I025: Acute natriuretic effect of telmisartan in hypertensive patients. Am. J. Hypertens. 13(S2): 183A. doi:10.1016/s0895-7061(00)01171-7.
10. Collino, M., Aragno, M., Castiglia, S., Miglio, G., Tomasinelli, C., Boccuzzi, G., Thiemermann, C., and Fantozzi, R. 2010. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br. J. Pharmacol. 160(8): 1892–1902. doi:10.1111/j.1476-5381.2010.00671.x. PMID:20233219.
11. de Kloet, A.D., Krause, E.G., and Woods, S.C. 2010. The renin angiotensin system and the metabolic syndrome. Physiol. Behav. 100(5): 525–534. doi:10.1016/j.physbeh.2010.03.018. PMID:20381510.
12. de Luis, D., Conde, R., González-Sagrado, M., Aller, R., Izaola, O., Dueñas, A., Castrillón, J.P., and Romero, E. 2010. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr. Hosp. 25(2): 275–279. PMID:20449538.
13. Derosa, G., Ragonesi, P.D., Mugellini, A., Ciccarelli, L., and Fogari, R. 2004. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res. 27(7): 457–464. doi:10.1291/hypres.27.457. PMID:15302981.
14. Diamant, M., and Heine, R.J. 2003. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs, 63(13): 1373–1405. doi:10.2165/00003495-200363130-00004. PMID:12825962.
15. Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Skene, A.M., Tan, M.H., Lefèbvre, P.J., Murray, G.D., et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro- Vascular Events): a randomised controlled trial. Lancet, 366(9493): 1279–1289. doi:10.1016/S0140-6736(05)67528-9. PMID:16214598.
16. Duez, H., Chao, Y.-S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C.A., Tedgui, A., et al. 2002. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor agonist fenofibrate in mice. J. Biol. Chem. 277(50): 48051–48057. doi:10.1074/jbc.M206966200. PMID:12377786.
17. Endo, Y., Suzuki, M., Yamada, H., Horita, S., Kunimi, M., Yamazaki, O., Shirai, A., Nakamura, M., Iso, O.N., Li, Y., et al. 2011. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ -dependent nongenomic signaling. Cell Metab. 13(5): 550–561. doi:10.1016/j.cmet.2011.02.015. PMID:21531337.
18. Finelli, C., and Tarantino, G. 2012a. Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease. World J. Gastroenterol. 18(46): 6790–6800. doi:10.3748/wjg.v18.i46.6790. PMID:23239917.
19. Finelli, C., and Tarantino, G. 2012b. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients. J. Gastrointestin. Liver Dis. 21(3): 293–302. PMID:23012671.
20. Fujimoto, M., Masuzaki, H., Tanaka, T., Yasue, S., Tomita, T., Okazawa, K., Fujikura, J., Chusho, H., Ebihara, K., Hayashi, T., Hosoda, K., and Nakao, K. 2004. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576(3): 492–497. doi:10.1016/j.febslet.2004.09.027. PMID:15498586.
21. Galle, J., Schwedhelm, E., Pinnetti, S., Boger, R.H., Wanner, C., and Vivaldi investigators. 2008. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol. Dial. Transplant. 23(10): 3174–3183. doi:10.1093/ndt/gfn230. PMID:18450829.
22. Gastaldelli, A., Casolaro, A., Ciociaro, D., Frascerra, S., Nannipieri, M., Buzzigoli, E., and Ferrannini, E. 2009. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. Am. J. Physiol. 297(1): E225–E230. doi:10.1152/ajpendo.90960.2008.
23. Ghosh, S.S., Gehr, T.W., Ghosh, S., Fakhry, I., Sica, D.A., Lyall, V, and Schoolwerth, A.C. 2003. PPARγ ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int. 64(1): 52–62. doi:10.1046/j.1523-1755.2003.00054.x. PMID:12787395.
24. Göke, B., and German Pioglitazone Study. 2002. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treatments Endocrinol. 1(5): 329–336. doi:10.2165/00024677-200201050-00005.
25. Guan, Y., Zhang, Y., Schneider, A., Davis, L., Breyer, R.M., and Breyer, M.D. 2001. Peroxisome proliferator-activated receptor-_ activity is associated with renal microvasculature. Am. J. Physiol. 281(6): F1036–F1046. doi:10.1152/ajprenal.0025.2001.
26. Haque, S. 2012. Peroxisome proliferators activated receptor-_ agonists: pioglitazone and telmisartan: potential therapeutic approaches to the metabolic syndrome. J. Diabetol. 1: 2.
27. Heimbach, E.J., Bowden, R.G., Griggs, J.O., Beaujean, A., Doyle, E.I., and Doyle, R.D. 2012. The effects of lowering uric acid levels using allopurinol on components of metabolic syndrome. Cardiol. Res. 3(2): 80–86. doi:10.4021/cr168w.
28. Hwang, J., Kleinhenz, D.J., Lassègue, B., Griendling, K.K., Dikalov, S., and Hart, C.M. 2005. Peroxisome proliferator-activated receptor-_ ligands regulate endothelial membrane superoxide production. Am. J. Physiol. 288(4): C899–C905. doi:10.1152/ajpcell.00474.2004.
29. Jayapriya, B., Thamilarasi, S., Shanthi, M., and Jafrin, A.L. 2013. Effect of telmisartan on blood pressure and lipid profile in hypertensive patients with dyslipidemia. Int. J. Clin. Pharmacol. Res. 4(10).
30. Kakuta, H., Sudoh, K., Sasamata, M., and Yamagishi, S. 2005. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int. J. Clin. Pharmacol. Res. 25(1): 41–46. PMID:15864875.
31. Kanbay, M., Ozkara, A., Selcoki, Y., Isik, B., Turgut, F., Bavbek, N., Uz, E., Akcay, A., Yigitoglu, R., and Covic, A. 2007. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int. Urol. Nephrol. 39(4): 1227–1233. doi: 10.1007/s11255-007-9253-3. PMID:17701281.
32. Kelishadi, R., Mansourian, M., and Heidari-Beni, M. 2014. Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. Nutrition, 30(5): 503–510. doi:10.1016/j.nut.2013.08.014. PMID:24698343.
33. Khan, A.R., Al Abdul Lateef, Z.N., Khamseen, M.B., Al Aithan, M.A., Khan, S.A., and Al Ibrahim, I. 2011. Knowledge, attitude and practice of ministry of health primary health care physicians in the management of type 2 diabetes mellitus: a cross-sectional study in the Al Hasa District of Saudi Arabia, 2010. Niger. J. Clin. Pract. 14(1): 52–59. doi:10.4103/1119-3077.79241.
34. Kimura, T., Kaneto, H., Shimoda, M., Hirukawa, H., Okauchi, S., Kohara, K., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., and Kaku, K. 2015. Protective effects of pioglitazone and/or liraglutide on pancreatic beta-cells in db/db mice: comparison of their effects between in an early and advanced stage of diabetes. Mol. Cell. Endocrinol. 400: 78–89. doi:10.1016/j.mce.2014.11.018. PMID:25463759.
35. Knight, S.F., Quigley, J.E., Yuan, J., Roy, S.S., Elmarakby, A., and Imig, J.D. 2008. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension, 51(2): 352–359. doi:10.1161/HYPERTENSIONAHA.107.099499. PMID:18158349.
36. Knorr, M., Hausding, M., Kröller-Schuhmacher, S., Steven, S., Oelze, M., Heeren, T., Scholz, A., Gori, T., Wenzel, P., Schulz, E., et al. 2011. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler., Thromb., Vasc. Biol. 31(10): 2223–2231. doi:10.1161/ATVBAHA.111.232058. PMID:21757654.
37. Kong, X., Ma, M.Z., Qin, L., Zhang, Y., Li, X.Y., Wang, G.D., Su, Q., and Zhang, D.Y. 2014. Pioglitazone enhances the blood pressure-lowering effect of losartan via synergistic attenuation of angiotensin II-induced vasoconstriction. Journal of the Renin–Angiotensin–Aldosterone system (JRAAS), 15(3): 259–270. doi:10.1177/1470320313489061.
38. Kutoh, E., and Hori, T. 2013. Effect of pioglitazone on serum uric acid levels in newly diagnosed, drug-naive patients with type 2 diabetes. Endocr. Res. 38(3): 151–159. doi:10.3109/07435800.2012.745128.
39. Lardizabal, J.A., and Deedwania, P.C. 2010. The role of renin–angiotensin agents in altering the natural history of type 2 diabetes mellitus. Curr. Cardiol. Rep. 12(6): 464–471. doi:10.1007/s11886-010-0138-1. PMID:20809236.
40. Larsen, T., Toubro, S., and Astrup, A. 2003. PPARγ agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int. J. Obes. 27(2): 147–161. doi:10.1038/sj.ijo.802223.
41. Lin, J.D., Chiou, W.K., Chang, H.Y., Liu, F.H., and Weng, H.F. 2007. Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism, 56(6): 751–756. doi:10.1016/j.metabol.2007.01.006. PMID:17512306.
42. Little, P.J., Ballinger, M.L., Survase, S., Osman, N., Ogru, E., Geytenbeek, S., Bruemmer, D., and Nigro, J. 2008. Phosphorylated troglitazone activates PPARγ and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis. J. Cardiovasc. Pharmacol. 51(3): 274–279. doi:10.1097/FJC.0b013e3181626ce7. PMID:18356692.
43. Liu, H.Z., Wang, Q.Y., Zhang, Y., Qi, D.T., Li, M.W., Guo, W.Q., Ma, Y.H., Wang, L.Y., Chen, Y., and Gao, C.Y. 2016. Pioglitazone up-regulates long noncoding RNA MEG3 to protect endothelial progenitor cells via increasing HDAC7 expression in metabolic syndrome. Biomed. Pharmacother. 78: 101–109. doi:10.1016/j.biopha.2016.01.001. PMID:26898430.
44. Mandarim-de-Lacerda, C.A., and Pereira, L.M. 2004. Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats. Histol. Histopathol. 19(3): 727–733. PMID:15168334.
45. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., and Turner, R.C. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7): 412–419. doi:10.1007/BF00280883. PMID:3899825.
46. Mazzali, M., Hughes, J., Kim, Y.G., Jefferson, J.A., Kang, D.H., Gordon, K.L., Lan, H.Y., Kivlighn, S., and Johnson, R.J. 2001. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension, 38(5): 1101–1106. doi:10.1161/hy1101.092839. PMID:11711505.
47. Miyazaki, Y., and DeFronzo, R.A. 2008. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes, Obes. Metab. 10(12): 1204–1211. doi:10.1111/j.1463-1326.2008.00880.x. PMID:18476983.
48. Mori, Y., Itoh, Y., and Tajima, N. 2007. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am. J. Hypertens. 20(4): 431–436. doi:10.1016/j.amjhyper.2006.09.016. PMID:17386352.
49. Morishima, M., Wang, Y., Akiyoshi, Y., Miyamoto, S., and Ono, K. 2009. Telmisartan, an angiotensin II type 1 receptor antagonist, attenuates T-type Ca2+ channel expression in neonatal rat cardiomyocytes. Eur. J. Pharmacol. 609(1–3): 105–112. doi:10.1016/j.ejphar.2009.03.024. PMID:19292980.
50. Nagi, M.N., al-Bekairi, A.M., and al-Sawaf, H.A. 1995. Spectrophotometric assay for superoxide dismutase based on the nitroblue tetrazolium reduction by glucose–glucose oxidase. Biochem. Mol. Biol. Int. 36(3): 633–638. PMID:7549963.
51. Nakagawa, T., Hu, H., Zharikov, S., Tuttle, K.R., Short, R.A., Glushakova, O., Ouyang, X., Feig, D.I., Block, E.R., and Herrera-Acosta, J. 2006. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. 290(3): F625–F631. doi:10.1152/ajprenal.00140.2005.
52. Olefsky, J.M. 2000. Treatment of insulin resistance with peroxisome proliferatoractivated receptor agonists. J. Clin. Invest. 106(4): 467–472. doi:10.1172/JCI10843. PMID:10953021.
53. Ono, Y., Nakaya, Y., Bando, S., Soeki, T., Ito, S., and Sata, M. 2009. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. Int. Heart J. 50(1): 73–83. doi:10.1536/ihj.50.73. PMID:19246848.
54. Osgood, D., Corella, D., Demissie, S., Cupples, L.A., Wilson, P.W., Meigs, J.B., Schaefer, E.J., Coltell, O., and Ordovas, J.M. 2003. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham Study. J. Clin. Endocrinol. Metab. 88(6): 2869–2879. doi:10.1210/jc.2002-021664. PMID:12788901.
55. Puig, J.G., and Martínez, M.A. 2008. Hyperuricemia, gout and the metabolic syndrome. Curr. Opin. Rheumatol. 20(2): 187–191. doi:10.1097/BOR.0b013e3282f4b1ed. PMID:18349749.
56. Rabie, E.M., Heeba, G.H., Abouzied, M.M., and Khalifa, M.M. 2015. Comparative effects of aliskiren and telmisartan in high fructose diet-induced metabolic syndrome in rats. Eur. J. Pharmacol. 760: 145–153. doi:10.1016/j.ejphar.2015.04.019. PMID:25917321.
57. Sánchez-Lozada, L.G., Tapia, E., Santamaría, J., Avila-Casado, C., Soto, V., Nepomuceno, T., Rodríguez-Iturbe, B., Johnson, R.J., and Herrera-Acosta, J. 2005. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 67(1): 237–247. doi:10.1111/j.1523-1755.2005.00074.x. PMID:15610247.
58. Sato, M., Iwanaga, T., Mamada, H., Ogihara, T., Yabuuchi, H., Maeda, T., and Tamai, I. 2008. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharmaceut. Res. 25(3): 639–646. doi:10.1007/s11095-007-9401-6.
59. Schupp, M., Janke, J., Clasen, R., Unger, T., and Kintscher, U. 2004. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor- activity. Circulation, 109(17): 2054–2057. doi:10.1161/01.CIR.0000127955.36250.65. PMID:15117841.
60. Shahin, D., El Toraby, E., Abdel-Malek, H., Boshra, V., Elsamanoudy, A.Z., and Shaheen, D. 2011. Effect of peroxisome proliferator-activated receptor agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study). Clin. Med. Insights: Arthritis Musculoskeletal Disord. 4: 1–10. doi:10.4137/CMAMD.S5951.
61. Sharma, A.M., Janke, J., Gorzelniak, K., Engeli, S., and Luft, F.C. 2002. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension, 40(5): 609–611. doi:10.1161/01.HYP.0000036448.44066.53. PMID:12411451.
62. Shokouh, P., Joharimoghadam, A., Roohafza, H., Sadeghi, M., Golabchi, A., Boshtam, M., and Sarrafzadegan, N. 2013. Effects of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients (EPICAMP Study): a double-blind, randomized clinical trial. PPAR Res. 2013: 358074. doi:10.1155/2013/358074. PMID:23710164.
63. Struthers, A.D., Donnan, P.T., Lindsay, P., McNaughton, D., Broomhall, J., and MacDonald, T.M. 2002. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart, 87(3): 229–234. doi:10.1136/heart.87.3.229. PMID:11847159.
64. Sung, B.H., Izzo, J.L., Jr., Dandona, P., and Wilson, M.F. 1999. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension, 34(1): 83–88. doi:10.1161/01.HYP.34.1.83. PMID:10406828.
65. Suzuki, H., Sakamoto, M., Hayashi, T., Iuchi, H., Ohashi, K., Isaka, T., Sakamoto, N., Kayama, Y., Tojo, K., Yoshimura, M., and Utsunomiya, K. 2013. Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc. Diabetol. 12: 71. doi:10.1186/1475-2840-12-71. PMID:23635096.
66. Suzuki, M., Nomura, C., Odaka, H., and Ikeda, H. 1997. Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. Jpn. J. Pharmacol. 74(4): 297–302. doi:10.1254/jjp.74.297. PMID:9307325.
67. Tarantino, G., Conca, P., Riccio, A., Tarantino, M., Di Minno, M.N., Chianese, D., Pasanisi, F., Contaldo, F., Scopacasa, F., and Capone, D. 2008. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J. Transl. Med. 6: 72. doi:10.1186/1479-5876-6-72. PMID: 19038040.
68. Verrier, E., Wang, L., Wadham, C., Albanese, N., Hahn, C., Gamble, J.R., Chatterjee, V.K.K., Vadas, M.A., and Xia, P. 2004. PPARγ agonists ameliorate endothelial cell activation via inhibition of diacylglycerol–protein kinase C signaling pathway role of diacylglycerol kinase. Circ. Res. 94(11): 1515–1522. doi:10.1161/01.RES.0000130527.92537.06. PMID:15117825.
69. Vu, A., Kosmiski, L.A., Beitelshees, A.L., Prigeon, R., Sidhom, M.S., Bredbeck, B., Predhomme, J., Deininger, K.M., and Aquilante, C.L. 2016. Pharmacodynamic effects of low-dose pioglitazone in patients with the metabolic syndrome without diabetes mellitus. Pharmacotherapy, 36: 252–262. doi:10.1002/phar.1713.
70. Watanabe, S., Kang, D.H., Feng, L., Nakagawa, T., Kanellis, J., Lan, H., Mazzali, M., and Johnson, R.J. 2002. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension, 40(3): 355–360. doi:10.1161/01.HYP.0000028589.66335.AA. PMID:12215479.
71. Weigert, C., Brodbeck, K., Bierhaus, A., Häring, H.U., and Schleicher, E.D. 2003. c-Fos-driven transcriptional activation of transforming growth factor γ-1: inhibition of high glucose-induced promoter activity by thiazolidinediones. Biochem. Biophys. Res. Commun. 304(2): 301–307. doi:10.1016/S0006-291X(03)00599-0. PMID:12711314.
72. Werner, C., Baumhäkel, M., Teo, K.K., Schmieder, R., Mann, J., Unger, T., Yusuf, S., and Böhm, M. 2008. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin. Res. Cardiol. 97(7): 418–431. doi:10.1007/s00392-008-0668-3. PMID:18454336.
73. Wu, S., Geng, X., Zhou, Y., and Wang, L. 2011. Effects of pioglitazone, repaglinide or metformin on blood uric acid and renal function in recent-onset type 2 diabetes. Chin. J. Modern Appl. Pharm. 2: 27.
74. Xiong, Z., Huang, H., Li, J., Guan, Y., and Wang, H. 2004. Anti-inflammatory effect of PPARγ in cultured human mesangial cells. Renal Fail. 26(5): 497–505. doi:10.1081/JDI-200031747.
75. Xu, L., and Liu, Y. 2013. Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/ eNOS pathway and NO release in spontaneously hypertensive rats. Physiol. Res. 62(4): 351–359. PMID:23590610.
76. Yuen, C.Y., Wong, W.T., Tian, X.Y., Wong, S.L., Lau, C.W., Yu, J., Tomlinson, B., Yao, X., and Huang, Y. 2011. Telmisartan inhibits vasoconstriction via PPARγ - dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc. Res. 90(1): 122–129. doi:10.1093/cvr/cvq392. PMID:21156825.
77. Zanchi, A., Dulloo, A.G., Perregaux, C., Montani, J.P., and Burnier, M. 2007. Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am. J. Physiol. 293(1): E91–E95. doi:10.1152/ajpendo.00024.2007.
78. Zhang, Q., Xiao, X., Li, M., Li, W., Yu, M., Zhang, H., Sun, X., Mao, L., and Xiang, H. 2012. Telmisartan improves kidney function through inhibition of the oxidative phosphorylation pathway in diabetic rats. J. Mol. Endocrinol. 49(1): 35–46. doi:10.1530/JME-12-0020. PMID:22591908.